Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CHELATEC<br />
1 rue Aronnax<br />
44821 SAINT-HERBLAIN Cedex - FRANCE<br />
Phone: +33 2 51 86 19 59<br />
Fax: +33 2 51 86 15 65<br />
Email: jfgestin@chel<strong>at</strong>ec.fr<br />
Web site: www.chel<strong>at</strong>ec.fr<br />
Contact: Jean-François GESTIN<br />
Chel<strong>at</strong>ec is an independent company providing customized service in the specific<br />
fields of radiolabeling and preclinical research.<br />
Our mission is to assist the pharmaceutical and biotechnology industry in the<br />
identific<strong>at</strong>ion and selection process of drug candid<strong>at</strong>es using the radioactive tracer.<br />
The broad expertise of our multidisciplinary team and the quality of our technical<br />
resources guarantee you optimum support for subcontracted projects. We offer a<br />
unique environment of labor<strong>at</strong>ories accredited in both the handling of radionuclides<br />
and animal experiment<strong>at</strong>ion conducted on rodents.<br />
CILOA<br />
cc107 - B<strong>at</strong>iment 24<br />
Universite Montpellier II - Place E. B<strong>at</strong>aillon<br />
34095 MONTPELLIER Cedex 05 - FRANCE<br />
Phone: +33 4 67 14 39 97<br />
Fax: +33 4 67 14 42 86<br />
Email: robert.mamoun@univ-montp2.fr<br />
Web site: www.ciloaweb.com<br />
Contact: Robert MAMOUN<br />
Ciloa is a start-up company with a proprietary technology th<strong>at</strong> provides fully n<strong>at</strong>ive<br />
membrane proteins on n<strong>at</strong>ural nanovesicles. Single and multi-transmembrane<br />
domain proteins sorted on these vesicles harbor all their n<strong>at</strong>ural post-transl<strong>at</strong>ional<br />
modific<strong>at</strong>ions. This revolutionary pl<strong>at</strong>form allows to produce custom membrane<br />
proteins out of cells for:<br />
1) drug screening<br />
2) innov<strong>at</strong>ive therapies<br />
3) gener<strong>at</strong>ion of new vaccines & monoclonal antibodies<br />
4) developing new kind of diagnostic tools.<br />
34
Change language